Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | PAM | P19021 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868913 | 1.00 | GRIK1 (0.38) | GRIK1GRIK2PAMHTR2ACYP2C19 | |
| SCHEMBL4868911 | 0.81 | GRIK1 (0.38) | GRIK1GRIK2PAMHTR2AKMT2A | |
| SCHEMBL3514736 | 0.76 | ALOX15 (0.37) | KMT2A | |
| SCHEMBL4874787 | 0.74 | GRIK1 (0.39) | GRIK1NPC1KMT2A | |
| SCHEMBL4865809 | 0.73 | MAPT (0.39) | GRIK1 | |
| SCHEMBL4869117 | 0.73 | TSHR (0.36) | CYP2C19TSHRKMT2A | |
| SCHEMBL4868966 | 0.72 | KMT2A (0.43) | CYP2C19KMT2AMMP9 | |
| SCHEMBL4871616 | 0.71 | SLC1A3 (0.39) | — | |
| SCHEMBL6682067 | 0.71 | GGPS1 (0.45) | KMT2AMMP9 | |
| SCHEMBL4874127 | 0.71 | KMT2A (0.31) | KMT2AMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1599487-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | Givaudan SA (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004043971-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | GRIK1 22/4885GRIK2 58/4885PAM 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.